Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12241538 | 0.92 | GPR119 (0.85) | GPR119CYP2C9KCNH2 | |
| SCHEMBL386787 | 0.89 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL4719718 | 0.89 | GPR119 (0.79) | GPR119CYP2C9KCNH2 | |
| SCHEMBL386244 | 0.88 | GPR119 (0.79) | GPR119CYP2C9 | |
| SCHEMBL389852 | 0.88 | GPR119 (0.79) | GPR119CYP2C9KCNH2 | |
| SCHEMBL386487 | 0.88 | GPR119 (0.78) | GPR119CYP2C9KCNH2 | |
| SCHEMBL391292 | 0.87 | GPR119 (0.77) | GPR119CYP2C9KCNH2 | |
| SCHEMBL386797 | 0.87 | GPR119 (0.77) | GPR119CYP2C9 | |
| SCHEMBL389810 | 0.87 | GPR119 (0.77) | GPR119CYP2C9KCNH2 | |
| SCHEMBL390706 | 0.87 | GPR119 (0.77) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | claimed |
| EP-1756084-B1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1756084-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005121121-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | claimed |
| EP-2731944-A1 | GPR 119 MODULATORS | Pfizer Inc (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2643310-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130072427-A1 | GPR 119 MODULATORS | PFIZER INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2013011402-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| EP-1758565-B2 | Method of identifying GLP-1 secretagogues | ARENA PHARM INC (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-2504342-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | Pfizer Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2480551-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1808168-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1756084-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2005121121-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | GPR119 2/4885CYP2C9 3655/4885KCNH2 3954/4885 |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | GPR119 2/4885CYP2C9 3655/4885KCNH2 3954/4885 |
| US-20130072427-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | GPR119 1/4885CYP2C9 1406/4885KCNH2 2347/4885 |
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP11B1 | GPR119 31/4885CYP2C9 54/4885KCNH2 4532/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | GPR119 2/4885CYP2C9 3655/4885KCNH2 3954/4885 |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | GPR3, GPR119, GPR84 | GPR119 2/4885CYP2C9 1481/4885KCNH2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.